Substituted pyrrolopyridines as atr inhibitors

Abstract

The disclosure includes compounds of Formula (I) wherein A, W, m, R 5 , R 6 , R 7 , and R 8 , are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.

What is claimed is: 
     
         1 . A compound of Formula (I), or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of Formula (I) or N-oxide thereof: 
       
         
           
           
               
               
           
         
         wherein
 A is 
 
       
       
         
           
           
               
               
           
         
         each of R 3 , and R 4 , independently, is H, D, halo, alkyl, or halo-alkyl; or R 3  and R 4  together with the atom to which they are attached forms a cycloalkyl or heterocycloalkenyl;
 Z is H, D, OH, halo, amine, cyano, C(O)OH, C(O)NH 2 , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl of Z is optionally substituted with one or more R d ; 
 W is N or C(R a ); 
 each of R 5 , R 6 , R 7 , and R 8 , independently, is H, D, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, cyano, OR a , SR a , alkyl-R a , NH(CH 2 ) p R a , C(O)R a , S(O)R a , SO 2 R a , C(O)OR a , OC(O)R a , NR b R c , P(O)R b R c , alkyl-P(O)R b R c , C(O)N(R b )R c , N(R b )C(O)R c , S(O)(═N(R b ))R c , —N═S(O)R b R c , SO 2 N(R b )R c , or N(R b )SO 2 R c , in which said cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally substituted with one or more R d ; 
 R a , R b , R c  and R d , independently, is H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, ═O, C(O)NHOH, C(O)OH, C(O)NH 2 , alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl, in which said alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl is optionally substituted with one or more R e ; 
 R e  is H, D, alkyl, alkenyl, alkynyl, halo, cyano, amine, nitro, hydroxy, ═O, C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, alkylamino, oxo, halo-alkylamino, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl; and 
 m, and n, independently, is 0, 1, 2, or 3. 
 
       
     
     
         2 . The compound according to  claim 1  or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug thereof, wherein the compound is represented by Formula (II) 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound according to  claim 1  or an N-oxide thereof, or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug thereof, wherein the compound is
 (R)-2-methyl-2-(6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)propanenitrile, 
 (R)-4-(2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-6-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrimidin-4-yl)-3-methylmorpholine, 
 1,1,1-trifluoro-2-(6-((R)-3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)propan-2-ol, 
 (R)-2-(6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)propan-2-ol, 
 (R)-2-(6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-yl)propan-2-amine, 
 (R)—N-((3,3-difluorocyclobutyl)methyl)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine; 
 6-((R)-3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N—(((S)-tetrahydrofuran-3-yl)methyl)pyrimidin-4-amine, 
 6-((R)-3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N—(((R)-tetrahydrofuran-3-yl)methyl)pyrimidin-4-amine, 
 (R)-6-(3-methylmorpholino)-N-(oxetan-3-ylmethyl)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine, 
 (R)—N-((4,4-difluorocyclohexyl)methyl)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine, 
 (R)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)pyrimidin-4-amine, 
 (R)—N-ethyl-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine, 
 (R)—N-(2-fluoro-2-methylpropyl)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine, 
 (R)—N-(3,3-difluorocyclobutyl)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine, 
 (R)—N-(cyclopropylmethyl)-6-(3-methylmorpholino)-2-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrimidin-4-amine. 
 
     
     
         4 . A pharmaceutical composition comprising a compound of Formula (I) or an N-oxide thereof as defined in  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of Formula (I) or an N-oxide thereof, and a pharmaceutically acceptable diluent or carrier. 
     
     
         5 . A method of treating a neoplastic disease, autoimmune disease, and inflammatory disorder, comprising administering to a subject in need thereof an effective amount of a compound of Formula (I) or an N-oxide thereof as defined in  claim 1 , or a pharmaceutically acceptable salt, solvate, polymorph, tautomer, stereoisomer, an isotopic form, or a prodrug of said compound of Formula (I) or an N-oxide thereof.